NEW YORK, Sept. 12, 2025 /PRNewswire/ -- An affiliate of the fund known as EQT VIII ("EQT") is pleased to announce the completion of an underwritten public offering (the "Offering") of c. 18.0 million shares of common stock of Waystar Holding Corp. (NASDAQ: WAY) (the "Company") ("Shares"), for aggregate proceeds of c. USD 705.8 million to all the selling stockholders. As part of the Offering, EQT sold c. 7.8 million Shares (and now holds c. 24.9 million Shares) and received proceeds of c. USD 304.5 million. The remaining Shares sold in the Offering were sold by other stockholders of the Company. J.P. Morgan Securities LLC acted as underwriter of the Offering, which was completed on September 12, 2025. The Company did not sell any Shares in the Offering and did not receive any proceeds from the sale of the Shares sold by EQT and the other stockholders.
Contact
EQT Press Office, This email address is being protected from spambots. You need JavaScript enabled to view it.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
Press Release, EQT VIII, Waystar, 120925 |
| Last Trade: | US$37.36 |
| Daily Change: | -0.99 -2.58 |
| Daily Volume: | 3,414,188 |
| Market Cap: | US$6.510B |
September 10, 2025 September 09, 2025 July 30, 2025 July 23, 2025 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
